Morgan Stanley
ORIC icon

Morgan Stanley’s Oric Pharmaceuticals ORIC Stock Holding History

Morgan Stanley’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4M Buy
1,794,020
+111,497
+7% +$1.01M ﹤0.01% 3126
2026
Q1 		$21.3M Buy
1,682,523
+488,450
+41% +$5.54M ﹤0.01% 2894
2025
Q4 		$9.77M Buy
1,194,073
+448,545
+60% +$5.16M ﹤0.01% 3636
2025
Q3 		$8.95M Buy
745,528
+350,743
+89% +$3.69M ﹤0.01% 3644
2025
Q2 		$4.01M Buy
394,785
+226,114
+134% +$1.52M ﹤0.01% 4235
2025
Q1 		$941K Sell
168,671
-178,684
-51% -$1.56M ﹤0.01% 5027
2024
Q4 		$2.8M Sell
347,355
-24,372
-7% -$224K ﹤0.01% 4451
2024
Q3 		$3.81M Sell
371,727
-52,195
-12% -$516K ﹤0.01% 4173
2024
Q2 		$3M Buy
423,922
+123,099
+41% +$1.1M ﹤0.01% 4290
2024
Q1 		$4.14M Sell
300,823
-179,508
-37% -$2.13M ﹤0.01% 4060
2023
Q4 		$4.42M Buy
480,331
+356,140
+287% +$2.58M ﹤0.01% 4015
2023
Q3 		$751K Sell
124,191
-24,390
-16% -$200K ﹤0.01% 4959
2023
Q2 		$1.15M Buy
148,581
+54,552
+58% +$310K ﹤0.01% 4752
2023
Q1 		$536K Buy
94,029
+36,454
+63% +$190K ﹤0.01% 5212
2022
Q4 		$339K Buy
57,575
+19,885
+53% +$67.1K ﹤0.01% 5432
2022
Q3 		$121K Sell
37,690
-41,513
-52% -$166K ﹤0.01% 5984
2022
Q2 		$354K Buy
79,203
+6,006
+8% +$24K ﹤0.01% 5593
2022
Q1 		$391K Buy
73,197
+26,830
+58% +$242K ﹤0.01% 5553
2021
Q4 		$681K Buy
46,367
+27,453
+145% +$428K ﹤0.01% 5358
2021
Q3 		$396K Sell
18,914
-127,101
-87% -$2.58M ﹤0.01% 5634
2021
Q2 		$2.58M Buy
146,015
+133,130
+1,033% +$2.92M ﹤0.01% 4439
2021
Q1 		$316K Sell
12,885
-18,324
-59% -$579K ﹤0.01% 5394
2020
Q4 		$1.06M Buy
31,209
+30,270
+3,224% +$868K ﹤0.01% 4634
2020
Q3 		$23K Sell
939
-1,914
-67% -$45.6K ﹤0.01% 6009
2020
Q2 		$96K Buy
+2,853
New +$91.1K ﹤0.01% 5420

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley's ORIC Position: Q2 2026 in Review

Morgan Stanley increased its Oric Pharmaceuticals (ORIC) stake by 6.6% in Q2 2026, buying an estimated $1.01M and bringing the position to 1,794,020 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3126.

Morgan Stanley first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $21.3M in Q1 2026. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Morgan Stanley held 1,794,020 shares of Oric Pharmaceuticals worth $19.4M as of Q2 2026.
  • Morgan Stanley bought 111,497 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.01M.
  • Oric Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3126 holding.
  • Morgan Stanley first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Morgan Stanley's Oric Pharmaceuticals position peaked at $21.3M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.